← board
RFL
distress 1/10 · well-funded / low risk$1.98-9%today-48% from 52w high
Lead: Niemann-Pick Disease Type C
Revenue
pre-revenue
Liquidity
$31M
Runway
1.6 yrs
Shares 1y
—
Price & events
+65.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-9.2%
1D
-15.7%
1W
-25.8%
1M
+52.3%
3M
+63.6%
6M
-7.9%
1Y
+38.5%
2Y
-96.1%
5Y
-91.1%
All
Overview
- Market Cap
- $198
- Volume
- 50.66K
- 52 Week Range
- $1.16 – $3.78
- Total Shares
- 100
- Float Shares
- 31.83M
- Short %
- 0.62%
- % Held by Insiders
- 38.12%
- % Held by Institutions
- 7.33%
- RVOL
- 0.17x
- Beta
- 0.29
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 6
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)Trappsol Cyclo · NDA submission to FDASEC 8-K
- second half of 2026Guided 55%readoutPhase 3Trappsol Cyclo · Topline data from main study cohortSEC 8-K
- calendar Q3, 2026Guided 70%readoutPhase 3Trappsol Cyclo · Topline results from pivotal Phase 3 Transport NPC trialSEC 8-K
- first half of 2026readoutPhase 3Trappsol Cyclo · Final analysis of TransportNPC Phase 3 trialSEC 8-K
- 2026-04-22partnershipTrappsol Cyclo · Exclusive licensing agreement with MIT for patent covering cyclodextrins in ApoE4-positive Alzheimer's diseaseSEC 8-K
- 2025-06-18fda agreementTrappsol Cyclo · FDA accepted statistical analysis plan for TransportNPC studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Niemann-Pick Disease Type C
- ZVRAZEVRA THERAPEUTICS, INC.$705M · D0
Recent news
- 2026-07-20Press Release: Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results - Moomoo
- 2026-07-17Rafael Holdings, Inc. (NYSE:RFL) Sees Large Growth in Short Interest - MarketBeat
- 2026-07-16Rafael Holdings Inc (RFL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-09Rafael Holdings Inc. (RFL) Q1 2025 Earnings: Net Loss of $0.37 Per Share as Stock Declines 7.35% - Earnings Yield Spread - dars.gov.et
- 2026-07-08Rafael Holdings: Phase 3 LPLV complete; NDA submission and topline expected 2H 2026 - TradingView
- 2026-07-08Rafael Holdings (RFL) details late-stage Trappsol Cyclo program and 2026 NDA plans - Stock Titan
- 2026-06-29ETFs Investing in Rafael Holdings, Inc. Class B Stocks - TradingView
- 2026-06-29Rafael Holdings: 2H 2026 Could Define This Company Forever (NYSE:RFL) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.